Weight-Loss Drug Popularity Grows as Access Barriers

Why Are Weight-Loss Drugs Popular but Still Not Widely Used?

GLP-1 receptor agonists have attracted intense interest because randomized clinical trials found that some agents can produce substantially greater average weight loss than older obesity medicines. Semaglutide activates the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors. These pathways influence appetite, food intake and glucose regulation, helping many patients feel full sooner and eat less.

Popularity does not necessarily mean broad access. A nationally representative KFF survey published in 2024 found that about one in eight US adults reported ever using a GLP-1 medicine, while 6% said they were currently using one. The survey included use for diabetes, weight loss and other chronic conditions, so it should not be interpreted as an estimate of obesity treatment alone. Cost and insurance coverage were prominent concerns among respondents.

Who May Qualify for Prescription Weight-Loss Medication?

Eligibility depends on the medicine and its FDA-approved labeling. Drugs such as Wegovy and Zepbound are used alongside a reduced-calorie diet and increased physical activity. For adults, prescribing criteria generally include a body mass index of at least 30, or at least 27 with a weight-related condition such as hypertension, type 2 diabetes or abnormal cholesterol levels. BMI is a screening measure rather than a complete assessment of individual health.

These medicines are not suitable for everyone. Gastrointestinal effects such as nausea, vomiting, diarrhea and constipation are common, particularly while the dose is being increased. Product labeling also describes important precautions and contraindications. Clinicians should review a patient's medical history, concurrent medicines, pregnancy plans and potential risks before treatment begins.

What Determines Whether GLP-1 Treatment Works Long Term?

Obesity is a chronic, relapsing disease, and anti-obesity medication is usually considered part of long-term management rather than a short course. The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism, found that participants regained a substantial amount of weight after semaglutide treatment ended. This finding supports the need to discuss maintenance before starting therapy.

Follow-up care should evaluate weight change, metabolic health, side effects, nutrition and whether treatment remains affordable and clinically appropriate. Patients should obtain these drugs through licensed prescribers and pharmacies. Products marketed online as unapproved, counterfeit or loosely described as equivalent to FDA-approved medicines may not have the same evidence, manufacturing controls or safety oversight.